Envisia Therapeutics
http://www.envisiatherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Envisia Therapeutics
Deals Shaping The Medical Industry, November 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
Start-Up Execs On The Move, May 2015
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Execs On The Move, May 2015
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Nanotechnology, Chips, etc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice